D. E. Shaw & Co., Inc. Rapt Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 270,141 shares of RAPT stock, worth $756,394. This represents 0.0% of its overall portfolio holdings.
Number of Shares
270,141Holding current value
$756,394% of portfolio
0.0%Shares
9 transactions
Others Institutions Holding RAPT
# of Institutions
147Shares Held
29.2MCall Options Held
709KPut Options Held
1.06M-
Column Group LLC San Francisco, CA2.68MShares$7.51 Million15.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.49MShares$6.98 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.47MShares$6.92 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.03MShares$5.68 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.91MShares$5.33 Million0.0% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $83M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...